20 YEARS OF PROFESSIONAL & DEDICATED SERVICE TO GLOBAL CUSTOMERS

Custom Manufacturing, Project Outsourcing, your Trusted Partner from China

Understanding Teglicar: Synthesis, Stability, and Research Applications

The advancement of scientific research often hinges on the availability of high-quality, well-characterized chemical compounds. Teglicar (CAS 250694-07-6), a significant inhibitor of carnitine palmitoyltransferase 1A (L-CPT1), is one such compound that has garnered attention for its roles in metabolic research and oncology. For procurement managers and research scientists, understanding its synthesis, stability, and how to best source it is crucial.

Teglicar's synthesis typically involves a straightforward urea formation reaction. A common method employs the reaction between (R)-aminocarnitine and tetradecylisocyanate, often facilitated by a phase transfer catalyst. This reaction is designed to yield the target compound with high purity. However, a key challenge in working with compounds like Teglicar has historically been their stability, particularly their tendency to be hygroscopic and exist in amorphous forms.

Significant advancements have been made in developing stable crystalline forms of Teglicar, notably Crystalline Form I. This form exhibits superior stability and reduced hygroscopicity compared to amorphous preparations. The careful control of crystallization processes, often involving specific solvents and controlled temperature conditions, is essential for obtaining this highly pure and stable material. For research applications, the stability of the compound directly impacts the reliability and reproducibility of experimental results.

When considering the purchase of Teglicar, it is vital to partner with a reputable manufacturer and supplier. We, as a leading chemical supplier based in China, specialize in providing research-grade chemicals like Teglicar (CAS 250694-07-6). Our stringent quality control ensures that you receive compounds with guaranteed purity and stability. Understanding the needs of our B2B clientele, we offer competitive pricing and reliable supply chains, making it easier for research institutions and pharmaceutical companies to buy Teglicar for their ongoing projects. Trust us to be your supplier for critical research reagents.

Manufacturing Facilities

NINGBO INNO PHARMCHEM CO.,LTD. was established in 2007. It is committed to the R&D, production and sales of raw materials, pharmaceutical intermediates and fine chemicals. We striving to create a high-efficiency and high-quality integrated chemical service platform to better serve domestic and foreign customers.

Professional Export Experience

to Global Customers

WHY CHOSE US?

1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;

2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;

3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).

FAQ

  • A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.

  • A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.

  • A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.

CONTACT US
Should you need to contact us; you may call during regular business hours, Monday through Friday, 8am – 6 pm.
NINGBO INNO PHARMCHEM CO.,LTD.
Address: No.163 Ruiqing Rd.,Ningbo 315000 China
Phone: 86-574-87319282
Fax: 86-574-27912196
SEND US AN EMAIL

NAME*

EMAIL*

COMPANY

COUNTRY*

MESSAGE*

Previous: Teglicar: A Promising Agent in Oncology Research and Cancer Metabolism

Next: Sourcing Teglicar (CAS 250694-07-6): A Buyer's Guide to L-CPT1 Inhibitors

All Rights Reserved